SART3

Across TCGA pan-cancer cohorts, SART3 RNA differs between tumor and matched normal tissue in 16 of 18 cancer types tested, making tumor–normal expression one of SART3’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where SART3 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SART3 is over-expressed in tumor, although a few such as THCA and KICH show the opposite, repressed pattern.

BLCA, HNSC, and COAD are the cancer types where SART3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SART3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	All	III,IV	+0.589	<.001	12	view →
HNSC	Male	III,IV	+0.781	<.001	11	view →
COAD	Female	II,III,IV	+0.715	<.001	11	view →
KIRC	All	All	+0.405	<.001	11	view →
KIRP	All	II,III,IV	+0.668	.001	10	view →
STAD	Male	II,III,IV	+1.080	<.001	9	view →
LIHC	Female	II,III,IV	+1.064	<.001	9	view →
LUSC	Male	II,III,IV	+0.740	<.001	7	view →
BRCA	All	II,III,IV	+0.245	<.001	6	view →
CHOL	Male	All	+2.055	<.001	5	view →
THCA	All	II,III,IV	−0.295	.016	5	view →
READ	All	All	+0.541	.016	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 16 lineages.

SART3–BLCA

Open the BLCA breakdown →